Smith, J A, Birring, S S, Dicpinigaitis, P V, McGarvey, L P, Morice, A H, Pavord, I D, Satia, I, Green, S, Iskold, B, La Rosa, C, Li, Q, Martin Nguyen, A, Schelfhout, J & Muccino, D 2022, ' Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups ', Lung, vol. 200, no. 4, pp. 423-429 . https://doi.org/10.1007/s00408-022-00553-y Smith, J A, Birring, S S, Dicpinigaitis, P V, McGarvey, L P, Morice, A H, Pavord, I D, Satia, I, Green, S, Iskold, B, La Rosa, C, Li, Q, Martin Nguyen, A, Schelfhout, J & Muccino, D 2022, ' Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant : A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups ', Lung, vol. 200, no. 4, pp. 423-429 . https://doi.org/10.1007/s00408-022-00553-y
Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7 Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W-C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7 Lung
COUGH-1 and COUGH-2 Investigators 2022, ' Efficacy and safety of gefapixant, a P2X 3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials ', The Lancet, vol. 399, no. 10328, pp. 909-923 . https://doi.org/10.1016/S0140-6736(21)02348-5